Login to Your Account



Sellas, Shanghai Fosun terminate $530M cancer, diabetes deal

By Cornelia Zou
Staff Writer

Thursday, July 3, 2014
HONG KONG – Chinese pharmaceutical conglomerate Shanghai Fosun Pharmaceutical Group Co. Ltd. and Sellas Clinicals Holding AG have agreed to terminate an 8-month-old $530 million deal, which covered drug candidates for diabetes and cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription